Program
ifebemtinib
Also written as “IN10018”, “BI 853520” and “IN10018 in combination with PLD”.
Its studies are mostly in Ovarian Neoplasms · Neoplasms · Pancreatic Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InxMed (Shanghai) | 117 open or running | phase 3since Aug 29, 2025 | Sep 26, 2019 | Mar 24, 2027phase 2 · NCT06014528 |
| Boehringer Ingelheim | 20 open or running | phase 1since Apr 7, 2011 | Apr 7, 2011 | none ahead |
| Hangzhou Hanx Biopharmaceuticals | 11 open or running | phase 2since Nov 25, 2024 | Nov 25, 2024 | Dec 31, 2027phase 2 · NCT06708663 |
| InventisBio | 11 open or running | phase 2since May 13, 2022 | May 13, 2022 | Dec 31, 2027phase 2 · NCT05379946 |
| Shanghai Jeyou Pharmaceutical | 11 open or running | phase 3since Sep 13, 2026 | Sep 13, 2026 | Apr 2029phase 3 · NCT07833202 |
- Named in fosun pharma’s own pipeline as
IN10018 (FAK)
, phase 3, as of Sep 21, 2026 (source).
Also a collaborator on its studies: ranok-therapuetics-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 7, 2011First study: phase 1 study in NeoplasmsNew to Boehringer IngelheimBoehringer Ingelheim · NCT01335269 · 96 enrolled · Canada, Netherlands
- Jul 12, 2013Phase 1 study in NeoplasmsBoehringer Ingelheim · NCT01905111 · 21 enrolled · Japan, Taiwan
- Sep 26, 2019InxMed (Shanghai)'s first study: phase 1 study in MelanomaNew to InxMed (Shanghai)InxMed (Shanghai) · NCT04109456 · 51 enrolled · United States, Australia
- Mar 29, 2022Phase 1 study in Stomach NeoplasmsInxMed (Shanghai) · NCT05327231 · 33 enrolled · China
- May 13, 2022InventisBio's first study: phase 2 study in Solid TumorNew to InventisBioInventisBio · NCT05379946 · 92 enrolled · China
- Sep 15, 2022Phase 2 study in Platinum-resistant Ovarian CancerInxMed (Shanghai) · NCT05551507 · 150 enrolled · China
- Mar 28, 20232 phase 2 studiesInxMed (Shanghai) · NCT05827796, NCT05830539
- Jul 13, 2023Phase 2 study in Solid TumorInxMed (Shanghai) · NCT05982522
- Aug 8, 20232 phase 2 studiesInxMed (Shanghai) · NCT05994131, NCT06014528
- Sep 1, 2023Phase 2 study in Small Cell Lung Cancer Extensive StageInxMed (Shanghai) · NCT06030258 · 120 enrolled · China
- Nov 25, 2024Hangzhou Hanx Biopharmaceuticals's first study: phase 2 study in Biliary Tract NeoplasmsNew to Hangzhou Hanx BiopharmaceuticalsHangzhou Hanx Biopharmaceuticals · NCT06708663 · 124 planned · China
- Aug 29, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungInxMed (Shanghai) · NCT07174908 · 400 planned · China
- Feb 13, 2026Phase 2 study in Solid Tumor CancerInxMed (Shanghai) · NCT07441174 · 92 planned · China
- Sep 13, 2026Shanghai Jeyou Pharmaceutical's first study: phase 3 study in NSCLCNew to Shanghai Jeyou PharmaceuticalShanghai Jeyou Pharmaceutical · NCT07833202 · 416 planned · China
Ahead
- Mar 24, 2027Primary completion: phase 2 study in Ovarian Cancer RecurrentInxMed (Shanghai) · NCT06014528
- Dec 31, 2027Primary completion: phase 2 study in Biliary Tract NeoplasmsHangzhou Hanx Biopharmaceuticals · NCT06708663
- Dec 31, 2027Primary completion: phase 2 study in Solid TumorInventisBio · NCT05379946
- Sep 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungInxMed (Shanghai) · NCT07174908
TargetBeta
“An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) ”NCIt, by rule
“Focal adhesion kinase 1 inhibitor”ChEMBL 37, by rule
Other programs on PTK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07833202NSCLC · China | 3 | Not yet recruiting | Shanghai Jeyou Pharmaceutical | Apr 2029 | 416 |
| NCT07441174Solid Tumor Cancer · China | 2 | Recruiting | InxMed (Shanghai) | Feb 28, 2031 | 92 |
| NCT07174908Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | InxMed (Shanghai) | Sep 2028 | 400 |
| NCT06708663Biliary Tract Neoplasms · China | 2 | Recruiting | Hangzhou Hanx Biopharmaceuticals | Dec 31, 2027 | 124 |
| NCT06030258Small Cell Lung Cancer Extensive Stage · China | 2 | Active, not recruiting | InxMed (Shanghai) | Nov 20, 2025 | 120 |
| NCT06014528Ovarian Cancer Recurrent · China | 2 | Active, not recruiting | InxMed (Shanghai) | Mar 24, 2027 | 168 |
| NCT05994131NSCLC · China | 2 | Active, not recruiting | InxMed (Shanghai) | Sep 20, 2025 | 110 |
| NCT05982522Solid Tumor | 2 | Withdrawn | InxMed (Shanghai) | Dec 31, 2026 | 0 |
| NCT05830539Locally Advanced or Metastatic Solid Tumors · China | 2 | Completed | InxMed (Shanghai) | Aug 31, 2024 | 68 |
| NCT05827796Pancreatic Neoplasms · China | 2 | Active, not recruiting | InxMed (Shanghai) | Oct 11, 2025 | 70 |
| NCT05551507Platinum-resistant Ovarian Cancer · China | 2 | Active, not recruiting | InxMed (Shanghai) | May 11, 2026 | 150 |
| NCT05379946Solid Tumor · China | 2 | Active, not recruiting | InventisBio | Dec 31, 2027 | 92 |
| NCT05327231Stomach Neoplasms · China | 1 | Completed | InxMed (Shanghai) | Dec 3, 2021 | 33 |
| NCT04109456Melanoma · United States, Australia | 1 | Completed | InxMed (Shanghai) | Dec 20, 2024 | 51 |
| NCT01905111Neoplasms · Japan, Taiwan | 1 | Completed | Boehringer Ingelheim | Aug 2014 | 21 |
| NCT01335269Neoplasms · Canada, Netherlands | 1 | Completed | Boehringer Ingelheim | Sep 2015 | 96 |
How it is read
Names in the registry
- “IN10018”, 8 entries
- “BI 853520”, 2 entries
- “IN10018 in combination with PLD”, 1 entry
- “IN10018 in combination with RNK08954”, 1 entry
- “IN10018 in combination with D-1553”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 2 studies
- Neoplasms, 2 studies
- Pancreatic Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.